

30. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. *Ann Thorac Surg* 2003; 76: 2121–2131.
31. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. *J Thromb Haemost* 2010; 8: 2642–2650.
32. Pouplard C, May MA, Regina S, et al. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. *Br J Haematol* 2005; 128: 837–841.
33. Nuttall GA, Oliver jr. WC, Santrach PJ, et al. Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series. *Anesth Analg* 2003; 96: 344–350.
34. Lillo-Le Louët A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. *J Thromb Haemost* 2004; 2: 1882–1888.
35. Shantsila E, Lip GYH, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. *Chest* 2009; 135: 1651–1664.
36. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med* 1995; 332: 1330–1335.
37. Ahmed I, Majeed A, Powell R. Heparin-induced thrombocytopenia: diagnosis and management update. *Postgrad Med J* 2007; 83: 575–582.
38. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. *N Engl J Med* 2006; 355: 809–817.
39. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *J Thromb Haemost* 2006; 4: 759–765.
40. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. *Arch Intern Med* 2003; 163: 2518–2524.
41. Lazúr J. Heparínom indukovaná trombocytopenia. *Interná med* 2019; 19: 51–54.
42. Kubisz P, Hollý P, Staško J. Heparínom indukovaná trombocytopenia. In: Štvrtinová V et al. *Venózný tromboembolizmus*. Bratislava: SAP, 2018, 388 s.
43. Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-induced thrombocytopenia. *J Am Coll Cardiol* 1998; 31: 1449–1459.
44. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. *Blood Adv* 2018; 2: 3360–3392.
45. He Y, He H, Liu D, et al. Fondaparinux in a critically ill patient with heparin-induced thrombocytopenia. *Medicine* 2018; 97: 37.
46. Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. *Res Pract Thromb Haemost* 2018; 2: 678–683.
47. Al-Eidan FAS, Alrawkan S, Alshammary H, et al. Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia. *Ann Hematol* 2018; 47: 12.
48. Skelley JW, Kyle JA, Roberts RA. Novel oral anticoagulants for heparin-induced thrombocytopenia. *J Thromb Thrombolysis* 2016; 42: 172–178.
49. Sokol J, Nehaj F, Mokán M, et al. *Nové perorálne antikoagulantia*. Martin: Osveta. 2018. s. 266.
50. Walenga JM, Prechel M, Jeske WP, et al. Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin-induced thrombocytopenia. *Br J Haematol* 2008; 143: 92–99.
51. Walenga JM, Prechel M, Hoppensteadt D, et al. Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. *Clin Appl Thromb Hemost* 2013; 19: 482–487.
52. Linkins LA, Warkentin TE, Pai M, et al. Design of the rivaroxaban for heparin-induced thrombocytopenia study. *J Thromb Thrombolysis* 2014; 38: 485–492.
53. Aljabri A, Huckleberry Y, Karnes JH, et al. Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. *Blood* 2016; 128: 3043–3051.
54. Linkins LA, Warkentin TE, Pai M, et al. Abstract number 3468 Rivaroxaban for Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia Study. American Society of Hematology 57th annual meeting Orlando FL, 2016.
55. Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. *Blood* 2017; 130: 1104–1113.
56. Shatzel JJ, Crapster-Pregont M, Deloughery TG. Non-vitamin K antagonist oral anticoagulants for heparin-induced thrombocytopenia. A systematic review of 54 reported cases. *Thromb Haemost* 2016; 116: 397–400.
57. Kunk P, Macik BG, Brown J. Abstract number 3547 Non-Warfarin Oral Anticoagulants in Heparin-Induced Thrombocytopenia. American Society of Hematology 57th annual meeting Orlando FL, 2015.
58. Ng HJ, Than H, Teo EC. First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia. *Thromb Res* 2015; 135: 205–207.
59. Mirdamadi A. Dabigatran, a direct thrombin inhibitor, can be a life-saving treatment in heparin-induced thrombocytopenia. *ARYA Atheroscler* 2013; 9: 112–114.
60. Hantson P, Lambert C, Hermans C. Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia. *Blood Coagul Fibrinolysis* 2015; 26: 205–206.
61. Sartori M, Favaretto E, Cini M, et al. Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia. *J Thromb Thrombolysis* 2015; 40: 392–394.
62. Larsen PB, Jørgensen M, Friis-Hansen L, et al. Apixaban used for the management of heparin-induced thrombocytopenia in a 72-year-old woman with lung cancer. *Clin Case Rep* 2015; 3: 987–989.
63. Sharif M, Bay C, Vajo Z, et al. New oral anticoagulants in the treatment of heparin-induced thrombocytopenia. *Thromb Res* 2015; 135: 607–609.
64. Abouchakra L, Khabbaz Z, Abouassi S, et al. Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report. *J Thorac Cardiovasc Surg* 2015; 150: e19–e20.
65. Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year-old man. *CMAJ* 2014; 186: 929–933.
66. Sninská Z, Chudej J, Guman T, et al. *Primárna imúnna trombocytopenia: princípy klasifikácie, diagnostiky a liečby*. Bratislava: GlaxoSmithKline Slovensko, 2014, 57 s.
67. Majdák P, Kubík jr. J, Harmátová L. Prípád vlnajúceho infikovaného trombu v jugularis interna, septických pneumónií a heparínom indukovanej trombocytopenie. *Vnitř Lék* 2011; 57: 117–121.
68. Sárník S, Hofírek I. Opakovaná lokálna trombolýza u poranení a trombózy axilárny a podklíčkové žily. *Vnitř Lék* 2009; 55: 1102–1104.
69. Dulíček P, Chrobák L. *Trombocytopenie indukovaná heparínom*.